-
公开(公告)号:US20100204471A1
公开(公告)日:2010-08-12
申请号:US12446974
申请日:2007-10-22
申请人: Qing Dong , Victoria Feher , Stephen W. Kaldor , Naoki Tomita
发明人: Qing Dong , Victoria Feher , Stephen W. Kaldor , Naoki Tomita
IPC分类号: C07D413/02 , C07D239/10 , C07D405/02
CPC分类号: C07D239/545 , C07D239/557 , C07D401/12 , C07D403/06 , C07D405/12 , C07D413/06
摘要: Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
摘要翻译: 提供化合物,药物组合物,试剂盒和方法用于包含选自以下的化合物的MEK:其中变量如本文所定义。
-
公开(公告)号:US20100113413A1
公开(公告)日:2010-05-06
申请号:US12652570
申请日:2010-01-05
申请人: Qing Dong , Stephen W. Kaldor
发明人: Qing Dong , Stephen W. Kaldor
IPC分类号: A61K31/496 , C07D239/545 , A61K31/513 , C07D405/06 , C07D403/06 , A61K31/397 , A61P35/00 , A61P17/00
CPC分类号: C07D239/545 , C07D239/557 , C07D401/12 , C07D403/06 , C07D405/12 , C07D413/06
摘要: Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.
摘要翻译: 取代的1,3-二烷基-2,4-二氧代-6-(芳基氨基)-1,2,3,4-四氢嘧啶-5-异羟肟酸的化合物如下所示:其中变量如本文所定义,药物 提供其组合物用作MEK激酶的抑制剂。
-
公开(公告)号:US08470837B2
公开(公告)日:2013-06-25
申请号:US13450064
申请日:2012-04-18
申请人: Qing Dong , Stephen W. Kaldor
发明人: Qing Dong , Stephen W. Kaldor
IPC分类号: C07D487/04 , A61K31/513 , A61P35/00
CPC分类号: C07D471/04
摘要: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using the presently described compounds.
摘要翻译: 提供下式的化合物用于MEK:其中变量如本文所定义。 还提供了包含这些化合物的药物组合物,试剂盒和制品; 用于制备化合物的方法和中间体; 和使用目前描述的化合物的方法。
-
公开(公告)号:US20120202999A1
公开(公告)日:2012-08-09
申请号:US13450064
申请日:2012-04-18
申请人: Qing Dong , Stephen W. Kaldor
发明人: Qing Dong , Stephen W. Kaldor
IPC分类号: C07D471/04
CPC分类号: C07D471/04
摘要: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
摘要翻译: 提供下式的化合物用于MEK:其中变量如本文所定义。 还提供了包含这些化合物的药物组合物,试剂盒和制品; 用于制备化合物的方法和中间体; 以及使用所述化合物的方法。
-
公开(公告)号:US08030317B2
公开(公告)日:2011-10-04
申请号:US11958999
申请日:2007-12-18
申请人: Qing Dong , Stephen W. Kaldor
发明人: Qing Dong , Stephen W. Kaldor
IPC分类号: C07D471/04 , A61K31/519 , A61P35/00
CPC分类号: C07D471/04
摘要: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
-
公开(公告)号:US20110190261A1
公开(公告)日:2011-08-04
申请号:US13082259
申请日:2011-04-07
申请人: Qing Dong , Stephen W. Kaldor
发明人: Qing Dong , Stephen W. Kaldor
IPC分类号: A61K31/513 , C07D239/10 , C07D403/06 , A61K31/496 , A61P35/00 , A61P17/00
CPC分类号: C07D239/545 , C07D239/557 , C07D401/12 , C07D403/06 , C07D405/12 , C07D413/06
摘要: Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(pyrimidinylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.”
摘要翻译: 取代的1,3-二烷基-2,4-二氧代-6-(嘧啶基氨基)-1,2,3,4-四氢嘧啶-5-异羟肟酸的化合物如下所示:其中变量如本文所定义,药物 提供其组合物用作MEK激酶的抑制剂。
-
公开(公告)号:US20080255160A1
公开(公告)日:2008-10-16
申请号:US11958999
申请日:2007-12-18
申请人: Qing Dong , Xianchang Gong , Stephen W. Kaldor , Toufike Kanouni , Nicholas Scorah , Michael B. Wallace , Feng Zhou
发明人: Qing Dong , Xianchang Gong , Stephen W. Kaldor , Toufike Kanouni , Nicholas Scorah , Michael B. Wallace , Feng Zhou
IPC分类号: A61K31/519 , C07D487/02 , C12N9/99 , A61P35/00 , A61P9/10 , A61P11/06 , A61P13/12 , A61P17/00
CPC分类号: C07D471/04
摘要: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
摘要翻译: 提供下式的化合物用于MEK:其中变量如本文所定义。 还提供了包含这些化合物的药物组合物,试剂盒和制品; 用于制备化合物的方法和中间体; 以及使用所述化合物的方法。
-
公开(公告)号:US20080188453A1
公开(公告)日:2008-08-07
申请号:US11932615
申请日:2007-10-31
IPC分类号: A61K31/40 , C07D207/34 , C07D261/02 , A61K31/4245 , A61P35/00 , A61K31/397 , A61K31/42 , C07D271/07
CPC分类号: C07D207/34 , C07D403/04 , C07D403/06 , C07D413/12
摘要: Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
-
公开(公告)号:US20080125437A1
公开(公告)日:2008-05-29
申请号:US11876635
申请日:2007-10-22
申请人: Qing DONG , Victoria Feher , Stephen W. Kaldor , Naoki Tomita
发明人: Qing DONG , Victoria Feher , Stephen W. Kaldor , Naoki Tomita
IPC分类号: A61K31/495 , A61K31/496 , A61K31/4965 , C07D403/02
CPC分类号: C07D239/545 , C07D239/557 , C07D401/12 , C07D403/06 , C07D405/12 , C07D413/06
摘要: Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
摘要翻译: 提供化合物,药物组合物,试剂盒和方法用于包含选自以下的化合物的MEK:其中变量如本文所定义。
-
公开(公告)号:US20110065733A1
公开(公告)日:2011-03-17
申请号:US12900350
申请日:2010-10-07
申请人: Qing Dong , Stephen W. Kaldor
发明人: Qing Dong , Stephen W. Kaldor
IPC分类号: A61K31/519 , A61P33/00
CPC分类号: C07D471/04
摘要: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
摘要翻译: 提供下式的化合物用于MEK:其中变量如本文所定义。 还提供了包含这些化合物的药物组合物,试剂盒和制品; 用于制备化合物的方法和中间体; 以及使用所述化合物的方法。
-
-
-
-
-
-
-
-
-